Overview: Parathyroid Hormone-Related Protein TestIntroduction: The Parathyroid Hormone-Related Protein Test measures PTHRP to diagnose hypercalcemia or cancer, causing bone pain or nausea. Following 2023 ASCO guidelines, it uses immunoassays for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected malignancy-associated hypercalcemia.
Other Names: PTHRP Assay, Hypercalcemia Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: PTHRP testing began in the 1980s with hypercalcemia research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures PTHRP to diagnose hypercalcemia or cancer, guides treatment, and evaluates patients with bone pain or nausea.
Test Parameters: 1. PTHRP Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of bone pain, nausea, or cancer symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document bone pain, nausea, or history of cancer. Include current medications, especially bisphosphonates.
Consent: Written consent required, detailing the tests purpose, hypercalcemia/cancer implications, and risks of sample collection.
Procedural Considerations: Uses immunoassays to measure PTHRP levels. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for hypercalcemia or cancer diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Non-malignant conditions may elevate PTHRP.
Clinical Significance: Elevated PTHRP confirms malignancy-associated hypercalcemia, guiding cancer therapy or bisphosphonates. Normal levels may require imaging.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Serum calcium, intact PTH, or cancer imaging to confirm hypercalcemia/cancer diagnosis.
Test Limitations: Non-specific for certain cancers; clinical correlation is needed. Sample quality affects sensitivity.
References: ASCO Hypercalcemia Guidelines, 2023; Journal of Clinical Oncology, Stewart AF, 2022.
